CD19 and neoplasm: Despite no tumor development, the survival rate of the CD19-CAR-IL-15 T cell treated group was the lowest compared with the CD19-CAR and CD19-CAR-IL-15-IL-15Ra T cell-treated groups, in which all mice died within 70 days (Fig. 4B and D).